Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczemaAlready a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category Share XKey drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczemahttps://pharmaphorum.com/news/key-drug-in-sanofis-1-45bn-kymab-buyout-shows-promise-in-eczema/
